ABCSG 41/OlympiA Summary

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase-III-study to assess the efficacy and safety of olaparib vs. placebo as adjuvant treatment in patients with germline BRCA1/2-mutations and high risk HER2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

Start: 10/2014
Coordinating investigator: Singer, Christian; Vienna
Sample size: 1.500 (international), 37 (national)
(Click to enlarge)
ABCSG 41/Therapy